Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion

Polyclonal convergent evolution to PARPi resistance in a patient with metastatic breast cancer with gPALB2.

Authors

Institutions

Publication Details

Journal
JCO Precision Oncology
Published
2024-10-01
DOI
https://doi.org/10.1200/po.24.00254
Citations
5
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
1.41

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion

David Kamson, Faith Too, Archana Balan, Antonio C. Wolff et al.
5 citations
JCO Precision Oncology
PARP inhibition in cancer therapy
1.41
article

Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion

David Kamson, Faith Too, Archana Balan, Antonio C. Wolff, Christopher D. Gocke, Kory Kreimeyer, Rachel Karchin, Cesar A. Santa‐Maria, Jonathan Spiker, Jennifer Lehman, Paola Ghanem, Michael Conroy, Mohammad A. Alzubi, Laura Linville, Valsamo Anagnostou, Vered Stearns, Rima Couzi, Karisa C. Schreck, John Laterra, Taxiarchis Botsis, Jenna VanLiere Canzoniero, Dana Petry, Christine A. Pratilas, Jessica J. Tao, Christian F. Meyer, Rena R. Xian, Kala Visvanathan, Deborah K. Armstrong, Timsy Wanchoo, Katerina Karaindrou, Ying Zou, Ming‐Tseh Lin, Mohamed Sherief, Monique Makell, Maria Durham, Ting He, Mimi Najjar, Jaime Wehr, Maria Fatteh
article en
5 citations

Abstract

Polyclonal convergent evolution to PARPi resistance in a patient with metastatic breast cancer with gPALB2.

JCO Precision OncologyVol. 8(8)
Johns Hopkins University (US), Johns Hopkins Medicine (US), Sidney Kimmel Comprehensive Cancer Center (US)
Bristol-Myers Squibb, AstraZeneca, Instituto Tecnológico de Costa Rica, National Institutes of Health, Foundation Medicine
Good health and well-being
Openalex Percentile: Top 15%
PARP inhibition in cancer therapy
1.41
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.